Giuseppe Banna, Head of Translational Research and Clinical Trials Unit of Thoracic Tumours at Candiolo Cancer Institute IRCCS and Consultant Medical Oncologist for Lung and Urology at Portsmouth Hospitals University NHS Trust, shared a post on X by The Oncologist, adding:
“Deferred cytoreductive nephrectomy after ICI in RCC is feasible. High rates of tumor necrosis, some pT0 responses, and >50% of patients able to discontinue systemic therapy suggest potential for treatment de-escalation.”
Quoting The Oncologist’s post about their paper by Paulo S do Amaral et al.:
“Deferred cytoreductive nephrectomy after ICI therapy in metastatic RCC shows promising results, with 67% of patients having a partial radiological response and 54% discontinuing systemic therapy. Extensive necrosis may be a key marker for durable responses.”
Title: Clinical and pathological outcomes of deferred nephrectomy in patients with metastatic and locally advanced RCC after immune checkpoint inhibitors
Authors: Paulo S do Amaral, Kathryn E Beckermann, Jennifer B Gordetsky, Sam S Chang, Daniel D Joyce, Kerry Schaffer, Amy N Luckenbaugh, Morgan A Lambrecht, Elizabeth G Ryan, Daniel A Barocas, Kelvin A Moses, Brian I Rini
You can read the Full Article in The Oncologist.
More posts featuring Giuseppe Banna.
